New Option For Uncontrolled Epilepsy On Horizon As US Accepts Cenobamate NDA

New potentially effective therapy for drug-resistant epilepsy, seen as the most pressing unmet need in this market, is on the horizon as FDA begins approval review of SK’s cenobamate, also marking a first for the Korean pharma industry.

Epilepsy
US FDA begins NDA review of SK's Cenobamate • Source: Shutterstock

The US FDA has formally accepted SK Life Science Inc.’s new drug application (NDA) for cenobamate, the Korean firm's investigational antiepileptic for the treatment of partial-onset seizures in adults, paving the way for the company's goal of bringing to market an effective therapy for drug-resistant epilepsy, seen as the most pressing unmet medical need in this segment.

Cenobamate (YKP3089), discovered and developed by SK Biopharmaceuticals Co. Ltd. and SK Life Science, its US subsidiary, is also...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip